The Brand Name FULFLO Has Generic Salt :: ALFUZOSIN 

FULFLO  Is From Company Alembic Priced :: Rs. 80

FULFLO have ALFUZOSIN is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Benign prostatic hyperplasia (BPH)

Drug Dose ::

Oral Benign prostatic hyperplasia Adult: 2.5 mg tid. Max: 10 mg/day. 1st dose should be given before bedtime. Extended-release: 10 mg once daily. Elderly: Initially, 2.5 mg bid. Acute urinary retention: Extended-release: 10 mg once daily to be taken from 1st day of catheterisation. Duration: 3-4 days. Hepatic impairment: Mild to moderate: Initially, 2.5 mg daily, may increase to 2.5 mg bid according to response. Severe: Contraindicated.

Contraindication ::

Severe hepatic impairment; history of postural hypotension and micturition syncope; intestinal occlusion; severe renal insufficiency; lactation.

Drug Precautions ::

Elderly; hypertension; coronary insufficiency; angina (discontinue); renal or hepatic impairment. Monitor BP regularly. May affect ability to drive or operate machinery.

Drug Side Effects ::

Drowsiness, postural hypotension, syncope, asthenia, depression, headache, dry mouth, GI disturbances, edema, blurred vision, rhinitis, erectile disorders, tachycardia, palpitation, hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy.

Pregnancy category ::

2

Drug Mode of Action ::  

Alfuzosin is a quinazoline derivative which exhibits selectivity for ?1-adrenergic receptors in the lower urinary tract. Blockade of these adrenoreceptors causes relaxation of smooth muscle in the bladder neck and prostate, resulting in improvement in urine flow and a reduction in symptoms of benign prostatic hyperplasia (BPH).

Drug Interactions ::

Additive effect on QT interval prolongation when used w/ QT-prolonging drugs. Concomitant admin w/ other ?1-adrenergic blocking agents, atenolol or diltiazem may result in additive CV effects. Increased plasma alfuzosin concentrations w/ cimetidine. Potentially Fatal: Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir) increase plasma alfuzosin levels.